The University of Chicago Header Logo

Connection

Anthony T. Reder to Interferon-beta

Back to Details
This is a "connection" page, showing publications Anthony T. Reder has written about Interferon-beta.
Anthony T. Reder
Connection Strength
6.538
Interferon-beta
  1. Interferon-ß corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection. EBioMedicine. 2019 Nov; 49:269-283.
    View in: PubMed
    Score: 0.675
  2. Vitamin D enhances responses to interferon-ß in MS. Neurol Neuroimmunol Neuroinflamm. 2019 11; 6(6):e622.
    View in: PubMed
    Score: 0.673
  3. The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Mult Scler. 2013 Nov; 19(13):1765-72.
    View in: PubMed
    Score: 0.431
  4. Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins. Arch Neurol. 2012 Oct; 69(10):1303-9.
    View in: PubMed
    Score: 0.414
  5. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology. 2010 Jun 08; 74(23):1877-85.
    View in: PubMed
    Score: 0.353
  6. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008 Oct 28; 71(18):1390-5.
    View in: PubMed
    Score: 0.307
  7. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J Interferon Cytokine Res. 2008 May; 28(5):317-31.
    View in: PubMed
    Score: 0.305
  8. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Mult Scler. 2007 May; 13(4):459-70.
    View in: PubMed
    Score: 0.280
  9. Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: implications for control of apoptosis. Front Biosci. 2004 May 01; 9:1547-55.
    View in: PubMed
    Score: 0.231
  10. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021 Jun; 51:102935.
    View in: PubMed
    Score: 0.187
  11. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. CNS Drugs. 2021 03; 35(3):317-330.
    View in: PubMed
    Score: 0.186
  12. Injecting rationale into interferon-beta therapy. Neurology. 2000 Jun 13; 54(11):2034-5.
    View in: PubMed
    Score: 0.176
  13. Effects of an anti-IL-10 monoclonal antibody on rIFNbeta-1b-mediated immune modulation. Relevance to multiple sclerosis. J Neuroimmunol. 1998 Jan; 81(1-2):109-15.
    View in: PubMed
    Score: 0.149
  14. Interferon beta-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult Scler. 1996 Apr; 1(5):262-9.
    View in: PubMed
    Score: 0.132
  15. Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J Neuroimmunol. 1995 Aug; 61(1):27-34.
    View in: PubMed
    Score: 0.126
  16. Induction of a unique isoform of the NCOA7 oxidation resistance gene by interferon ß-1b. J Interferon Cytokine Res. 2015 Mar; 35(3):186-99.
    View in: PubMed
    Score: 0.119
  17. IFN-gamma, IFN-beta, and PGE1 affect monokine secretion: relevance to monocyte activation in multiple sclerosis. Cell Immunol. 1994 Sep; 157(2):428-38.
    View in: PubMed
    Score: 0.118
  18. Treatment with interferon beta for multiple sclerosis. JAMA. 2012 Oct 24; 308(16):1627; author reply 1627-8.
    View in: PubMed
    Score: 0.104
  19. Evidence-based medicine: promise and pitfalls. Mult Scler. 2012 Jul; 18(7):947-8.
    View in: PubMed
    Score: 0.102
  20. Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis. Pharmacogenomics J. 2013 Oct; 13(5):443-51.
    View in: PubMed
    Score: 0.101
  21. Interferon-beta treatment does not elevate cortisol in multiple sclerosis. J Interferon Res. 1992 Jun; 12(3):195-8.
    View in: PubMed
    Score: 0.101
  22. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNß-1b trial. Neurology. 2012 Apr 24; 78(17):1315-22.
    View in: PubMed
    Score: 0.100
  23. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon ß-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012 Mar; 83(3):282-7.
    View in: PubMed
    Score: 0.098
  24. Fingolimod for the treatment of relapsing multiple sclerosis. Expert Rev Neurother. 2011 Feb; 11(2):165-83.
    View in: PubMed
    Score: 0.091
  25. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010 Jul; 9(7):740-50.
    View in: PubMed
    Score: 0.089
  26. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry. 2010 Aug; 81(8):907-12.
    View in: PubMed
    Score: 0.088
  27. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b. Mult Scler. 2010 Jan; 16(1):30-8.
    View in: PubMed
    Score: 0.085
  28. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clin Ther. 2009 Aug; 31(8):1724-36.
    View in: PubMed
    Score: 0.083
  29. IFN-beta-regulated genes show abnormal expression in therapy-naïve relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions. J Neuroimmunol. 2008 Mar; 195(1-2):116-20.
    View in: PubMed
    Score: 0.075
  30. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2007 Mar 27; 68(13):977-84.
    View in: PubMed
    Score: 0.071
  31. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology. 2006 Feb 28; 66(4):472-6.
    View in: PubMed
    Score: 0.066
  32. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler. 2004 Apr; 10(2):126-38.
    View in: PubMed
    Score: 0.057
  33. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol. 2002 Aug; 129(1-2):205-15.
    View in: PubMed
    Score: 0.051
  34. Type I interferons inhibit interleukin-10 production in activated human monocytes and stimulate IL-10 in T cells: implications for Th1-mediated diseases. J Interferon Cytokine Res. 2002 Mar; 22(3):311-9.
    View in: PubMed
    Score: 0.050
  35. Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis. Mult Scler. 2021 12; 27(14):2219-2231.
    View in: PubMed
    Score: 0.047
  36. Monocyte activation in multiple sclerosis. Mult Scler. 1998 Jun; 4(3):162-8.
    View in: PubMed
    Score: 0.038
  37. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest. 1997 Jun 01; 99(11):2664-71.
    View in: PubMed
    Score: 0.036
  38. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology. 1996 Dec; 47(6):1463-8.
    View in: PubMed
    Score: 0.035
  39. Mechanisms of action of interferon-beta in multiple sclerosis. Springer Semin Immunopathol. 1996; 18(1):125-48.
    View in: PubMed
    Score: 0.032
  40. Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis. Ann Neurol. 1995 Oct; 38(4):625-32.
    View in: PubMed
    Score: 0.032
  41. Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS One. 2011; 6(11):e22444.
    View in: PubMed
    Score: 0.024
  42. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology. 2008 Jul 08; 71(2):136-44.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.